BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27083895)

  • 1. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
    Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
    Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
    Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
    Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
    Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
    J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
    Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
    Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
    Majima H; Ito T; Koyama N
    Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.
    Conforti R; Capasso R; Galasso R; Cirillo M; Taglialatela G; Galasso L
    Medicine (Baltimore); 2016 Sep; 95(36):e4585. PubMed ID: 27603348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumefactive multiple sclerosis which initially presented with brainstem encephalitis with a long-term follow-up.
    Mitsutake A; Sato T; Katsumata J; Nakamoto FK; Seki T; Maekawa R; Hideyama T; Shimizu J; Shiio Y
    Mult Scler Relat Disord; 2019 Jul; 32():23-26. PubMed ID: 31005827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
    Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
    Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
    Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
    Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
    Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
    Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-like lesions in multiple sclerosis.
    Jamroz-Wiśniewska A; Janczarek M; Belniak E; Stelmasiak Z; Bartosik-Psujek H
    Neurol Neurochir Pol; 2008; 42(2):161-7. PubMed ID: 18512174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
    Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
    J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
    Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
    J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.
    Li X; Miao X; Wang Y; Sun J; Gao H; Han J; Li Y; Wang Q; Sun C; Liu J
    Front Immunol; 2022; 13():1052678. PubMed ID: 36532021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
    Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
    Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vertebral hemangiomas in the thoracic spine of multiple sclerosis patients are connected with fewer demyelinating lesions at the same level. Possible impact on pathophysiology and clinical course.
    Anagnostouli M; Katsavos S; Kyrozis A; Gontika M; Voumvourakis KI; Kapaki E
    Neurol Res; 2016 Aug; 38(8):655-62. PubMed ID: 27625006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.